Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Accured Expenses (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Change in Accured Expenses data on record, last reported at $25.6 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 57.46% year-over-year to $25.6 million; the TTM value through Dec 2025 reached $25.4 million, up 39.86%, while the annual FY2025 figure was $25.4 million, 39.86% up from the prior year.
  • Change in Accured Expenses reached $25.6 million in Q4 2025 per APLS's latest filing, up from $7.1 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $65.3 million in Q2 2021 and bottomed at -$64.6 million in Q3 2021.
  • Average Change in Accured Expenses over 5 years is $3.1 million, with a median of $9.5 million recorded in 2023.
  • Peak YoY movement for Change in Accured Expenses: surged 15415.68% in 2021, then tumbled 742.69% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $31.7 million in 2021, then tumbled by 52.83% to $15.0 million in 2022, then dropped by 20.74% to $11.9 million in 2023, then skyrocketed by 37.11% to $16.2 million in 2024, then surged by 57.46% to $25.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $25.6 million in Q4 2025, $7.1 million in Q3 2025, and $22.9 million in Q2 2025.